206 related articles for article (PubMed ID: 15491750)
1. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
2. A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells.
Kondo C; Shibata K; Terauchi M; Kajiyama H; Ino K; Nomura S; Nawa A; Mizutani S; Kikkawa F
Int J Cancer; 2006 Mar; 118(6):1390-4. PubMed ID: 16187279
[TBL] [Abstract][Full Text] [Related]
3. Possible role of placental leucine aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma.
Suzuki Y; Shibata K; Kikkawa F; Kajiyama H; Ino K; Nomura S; Tsujimoto M; Mizutani S
Clin Cancer Res; 2003 Apr; 9(4):1528-34. PubMed ID: 12684429
[TBL] [Abstract][Full Text] [Related]
4. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
Arimoto T; Nakagawa S; Yasugi T; Yoshikawa H; Kawana K; Yano T; Taketani Y
Gynecol Oncol; 2007 Jan; 104(1):32-5. PubMed ID: 16996113
[TBL] [Abstract][Full Text] [Related]
5. Expression of placental leucine aminopeptidase is associated with a poor outcome in endometrial endometrioid adenocarcinoma.
Shibata K; Kikkawa F; Suzuki Y; Mizokami Y; Kajiyama H; Ino K; Nomura S; Nagasaka T; Mizutani S
Oncology; 2004; 66(4):288-95. PubMed ID: 15218296
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
8. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Papadimitriou CA; Bafaloukos D; Bozas G; Kalofonos H; Kosmidis P; Aravantinos G; Fountzilas G; Dimopoulos MA;
Gynecol Oncol; 2008 Jul; 110(1):87-92. PubMed ID: 18455782
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
Akram T; Maseelall P; Fanning J
Am J Obstet Gynecol; 2005 May; 192(5):1365-7. PubMed ID: 15902110
[TBL] [Abstract][Full Text] [Related]
12. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
[TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
Misawa A; Nagao M; Kushimoto T; Yasuda M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1901-5. PubMed ID: 19011339
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of endometrial carcinoma associated with lung metastasis by paclitaxel and carboplatin chemotherapy].
Tohya T; Onoda C; Yoshimura T; Kagami T
Gan To Kagaku Ryoho; 2004 Jun; 31(6):949-51. PubMed ID: 15222119
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
16. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Papadimitriou CA; Fountzilas G; Bafaloukos D; Bozas G; Kalofonos H; Pectasides D; Aravantinos G; Bamias A; Dimopoulos MA;
Gynecol Oncol; 2008 Oct; 111(1):27-34. PubMed ID: 18644619
[TBL] [Abstract][Full Text] [Related]
19. Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.
Mazgani M; Le N; Hoskins PJ;
Gynecol Oncol; 2008 Dec; 111(3):474-7. PubMed ID: 18929402
[TBL] [Abstract][Full Text] [Related]
20. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
